HealthSouth and Oracle have joined forces to build the first all-digital hospital, featuring patient beds with display screens connected to the Internet, electronic medical record storage, and digital imaging. A wireless communications network will
HealthSouth and Oracle have joined forces to build the first all-digital hospital, featuring patient beds with display screens connected to the Internet, electronic medical record storage, and digital imaging. A wireless communications network will provide secure access to medical records from anywhere in or outside the hospital. HealthSouth expects to spend up to $125 million over 24 to 32 months on the hospital, which will be built near the company’s 92-acre campus in suburban Birmingham, AL. Oracle will develop healthcare software to support clinical applications and hospital operations. Among the other companies involved in the project are GE Medical Systems and Visualization Technology, which will provide image-guided systems for cranial, spinal, orthopedic, and ENT surgery. HealthSouth provides outpatient surgery, diagnostic imaging, and rehabilitative services, while Oracle specializes in e-business software.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.